Press Release November 14, 2018

Ginkgo Bioworks and Glycosyn LLC Announce $14 Million Partnership to Scale Production of Human Milk Oligosaccharides

The Life Sciences team advised Ginkgo Bioworks on its $14 million partnership with Glycosyn LLC to optimize and scale the production of human milk oligosaccharides (hMOS) for a suite of products that offer health benefits by fostering a healthy gut microbial ecology. Combining Glycosyn's experience in hMOS with Ginkgo's world-class organism engineering platform will drive new advances in and awareness of the widespread health benefits and applications of hMOS.

Under the terms of the agreement, Ginkgo’s $14 million investment in Glycosyn will include a mix of cash investment and foundry access. This investment in a specialty business is a milestone in Ginkgo's development as a platform, empowering companies like Glycosyn to build their products more efficiently, sustainably, and at scale.

Ginkgo Bioworks is the organism company, using the power of biology to build sustainable products in food, pharma, manufacturing, and more. Using sophisticated software and state of the art automation, Ginkgo's powerful platform for genetic engineering is making biology easier to engineer, enabling new products to be renewably manufactured with biology.

The Goodwin team was led by partner Karen Spindler and included partners Robert Puopolo, Theresa Kavanaugh and Mark Smith; and associate Megan Gustafson.

For additional details on the partnership, please read the press release.